Alpha Tau Medical (DRTS) Stock Price, News & Analysis

Company Overview

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $2.94 to $3.08
• 50-Day Range: $2.56 to $3.26
• 52-Week Range: $1.75 to $4.39
• Volume: 16,532 shs
• Average Volume: 50,162 shs
• Market Capitalization: $210.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Alpha Tau Medical Stock Analysis - MarketRank™

Alpha Tau Medical scored higher than 46% of companies evaluated by MarketBeat, and ranked 590th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alpha Tau Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.45) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Tau Medical is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Tau Medical is -6.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Tau Medical has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Tau Medical has recently decreased by 12.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Tau Medical does not currently pay a dividend.

Dividend Growth

Alpha Tau Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.19% of the float of Alpha Tau Medical has been sold short.

Short Interest Ratio / Days to Cover

Alpha Tau Medical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alpha Tau Medical has recently decreased by 12.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Alpha Tau Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.65% of the stock of Alpha Tau Medical is held by institutions.

DRTS Stock Analysis - Frequently Asked Questions

How have DRTS shares performed this year?

Alpha Tau Medical's stock was trading at $3.10 at the beginning of 2025. Since then, DRTS stock has decreased by 3.7% and is now trading at $2.9850.
View the best growth stocks for 2025 here.

How were Alpha Tau Medical's earnings last quarter?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced its earnings results on Monday, May, 19th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02.

Who are Alpha Tau Medical's major shareholders?

Top institutional investors of Alpha Tau Medical include Kovitz Investment Group Partners LLC (0.32%), Levin Capital Strategies L.P. (0.32%) and XTX Topco Ltd (0.03%).

How do I buy shares of Alpha Tau Medical?

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alpha Tau Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Tau Medical investors own include Datadog (DDOG), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), PayPal (PYPL), Sunrun (RUN) and ZIM Integrated Shipping Services (ZIM).

Company Calendar

• Last Earnings: 5/19/2025
• Today: 6/26/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DRTS
• CIK: 1871321
• Web: healthcarecapitalcorp.com
• Phone: 972-3577-4115
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +168.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.48%
• Return on Assets: -36.69%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.89 per share
• Price / Book: 3.35

Miscellaneous

• Outstanding Shares: 70,380,000
• Free Float: 42,581,000
• Market Cap: $210.08 million
• Optionable: No Data
• Beta: 0.99